Compare DexCom, Inc. (DXCM) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nerdwallet Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: DexCom, Inc. is far larger — about 51× Nerdwallet Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nerdwallet Inc for 45 Days on average.
| DXCM | NRDS | |
|---|---|---|
Market Cap | $31.86B | $625.17M |
Volume | 3,607,070 | 1,321,316 |
Sector | Health | Media |
52-Week High | $92.34 | $15.93 |
52-Week Low | $54.84 | $7.58 |
Typical Hold Time | 62 Days | 45 Days |
Enterprise Value | $31.32B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.
The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
